A Phase 1 interventional study of KD101 and placebo in Obesity, sponsored by Kwang Dong Pharmaceutical co., ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-03.
Sponsored by Kwang Dong Pharmaceutical co., ltd. · Phase 1 and Interventional
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
dose block-randomized, double-blinded, placebo controlled, single or multiple ascending dose study. AEs, PE, Vital signs, ECGs and Clinical lab tests
3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.
This study's planned enrollment of 38 is below the median of 73 across 3,175 interventional studies indexed under Overweight.
Browse Overweight studies →Kwang Dong Pharmaceutical co., ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: KD101
Drug: placebo
200mg, 400mg, 800mg, 1400mg
Also known as: KD101 soft capsule 200mg
200mg, 400mg, 800mg
Also known as: KD101 soft capsule 200mg placebo
Pharmacokinetic parameters - Cmax
Cmax (Maximum concentration of drug in plasma)
Time frame: up to 4 weeks
Pharmacodynamic parameters - PBMCs
PBMC (Peripheral blood mononuclear cell)
Time frame: up to 4 weeks
This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kwang Dong Pharmaceutical co., ltd.